The deep in-the-money warrants are almost certain to be exercised, triggering significant share issuance. Traders should anticipate sharp downward pressure on INM stock as dilution hits the market. Monitor for Form 3 filings and subsequent 8-Ks reporting exercise notices.
INM drugs
INM drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 28 $0.7010entry
- T+1 · 7mo ago 0.00%α +0.01% · $0.7010
- T+5 · 7mo ago +6.70%α +5.01% · $0.7480
- T+20 · 6mo ago +145.36%α +139.90% · $1.72
- T+60 · 4mo ago +163.91%α +159.92% · $1.85
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
InMed Pharmaceuticals amended preferred investment options (warrants) held by Sabby and H.C. Wainwright affiliates, reducing the exercise price from as high as $82.50 down to $0.80 per share. This makes the warrants deeply in-the-money relative to the current stock price (implied by the $2M market cap), enabling the holders to immediately purchase up to 2,304,714 common shares, more than doubling the outstanding shares and severely diluting existing shareholders.
Key Facts
- Sabby warrants amended to exercise price of $0.80 (was $2.436); Sabby can buy up to 2,151,478 shares.
- Wainwright warrants amended to exercise price of $0.80 (were as high as $82.50); Wainwright can buy up to 153,236 shares.
- Total potential new shares: 2,304,714 (excluding any other adjustments).
- Company market cap is $2M; the amendments enable massive dilution relative to current float.
- No financial figures (revenue, EPS) were provided in the filing.
Financial Impact
Potential proceeds up to $1.84M from warrant exercise, but at extreme dilution cost, shares could more than double outstanding count.
Risk Factors
- Massive shareholder dilution from warrant exercise.
- Potential decline in stock price as supply of shares increases.
- No mention of use of proceeds; cash raised likely insufficient to offset dilutive impact.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-048064 |
| Document: ea028772801ex10-2.htm | 0001213900-26-048064 |
| Document: ea028772801ex99-1.htm | 0001213900-26-048064 |
| Document: ea028772801ex10-1.htm | 0001213900-26-048064 |
| Document: 0001213900-26-048064-index-headers.html | 0001213900-26-048064 |
| Document: 0001213900-26-048064-index.html | 0001213900-26-048064 |
| Document: 0001213900-26-048064.txt | 0001213900-26-048064 |
Track record
22 reports on INM
6 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +24.51% at T+1 after the Nov 3, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 3, 202613d ago 8-K Bearish 6/10 Entry $1.75 Now $19.87 −1035.43% settles Dec 3
- Nov 2, 202614d ago 425 Neutral 3/10 Entry $1.68 Now $19.87 +1082.74% settles Dec 2
- Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
- Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
- Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
- Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
- Sep 9, 20269w ago 425 Neutral 6/10 Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers